Lasers in Medical Science

, Volume 4, Issue 2, pp 115–123

Tumour marking properties of different haematoporphyrins and tetrasulfonated phthalocyanine—A comparison

  • S. Andersson-Engels
  • J. Ankerst
  • J. Johansson
  • K. Svanberg
  • S. Svanberg


Several photosensitizers were screened for their tumour-marking ability using laserinduced fluorescence in Wistar/Furth rats bearing subcutaneous adenocarcinomas inoculated in muscle. Of the studied photosensitizers, dihaematoporphyrin ether appeared to exhibit the best tumour-demarcation properties. Polyhaematoporphyrin ester and tetrasulfonated phthalocyanine were almost as good although the fluorescence yield was much lower. Monomeric haematoporphyrin also showed some tumour-marking qualities. By forming fluorescence intensity ratios, information from both the blue and the red spectral regions were used to provide the highest tumour-to-muscle contrast. Two excitation wavelengths were used, of which 337 nm rather than 405 nm excitation light seemed to yield a better tumour demarcation, due to a greater difference in the superimposing autofluorescence between tumour and surrounding tissue. The study included measurements on many inner organs in an attempt to gain a better understanding of the interaction between the drugs and various kinds of tissue.

Key words

Cancer detection Fluorescence spectroscopy Haematoporphyrin derivative Laser excitation Phthalocyanine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bown SG, Carruth JAS, Jori G, Svaasand LO (eds).Lasers Med Sci 1988, International conference on Photodynamic Therapy and Medical Applications, Abstract issue, JulyGoogle Scholar
  2. 2.
    Dougherty TJ, Grindey GB, Fiel R et al. Photoradiation therapy II. Cure of animal tumours with hematoporphyrin and light.J Natl Cancer Inst 1975,55:115–19PubMedGoogle Scholar
  3. 3.
    Dougherty TJ, Kaufman JE, Goldfarb et al. Photoradiation therapy and treatment of malignant tumors.Cancer Res 1978,38:2628–35PubMedGoogle Scholar
  4. 4.
    Dougherty TJ, Lawrence G, Kaufman J et al. Photoradiation in the treatment of recurrent breast carcinoma.J Natl Cancer Inst 1979,62:231–7PubMedGoogle Scholar
  5. 5.
    Gomer CJ, Dougherty TJ. Determination of [3H]- and [14C]-hematoporphyrin derivative distribution in malignant and normal tissue.Cancer Res 1979,39:146–51PubMedGoogle Scholar
  6. 6.
    Bugelski PJ, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse.Cancer Res 1981,41:4606–12PubMedGoogle Scholar
  7. 7.
    Dougherty TJ. Photoradiation therapy for cutaneous and subcutaneous malignancies.J Invest Dermatol 1981,77:122–4PubMedGoogle Scholar
  8. 8.
    Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative.Arch Dermatol 1960,82:508–16PubMedGoogle Scholar
  9. 9.
    Moan J, Sommer S. Fluorescence and absorption properties of the components of hematoporphyrin derivative.Photobiochem Photobiophys 1981,3:93–103Google Scholar
  10. 10.
    Dougherty TJ, Boyle DG, Weishaupt KR et al. Photoradiation therapy: clinical and drug advances. In: Kessel D, Dougherty TJ (eds)Porphyrin Photosensitization. New York-London: Plenum 1983Google Scholar
  11. 11.
    Kessel D, Chou TH. Tumor localizing components of the porphyrin preparation hematoporphyrin derivative.Cancer Res 1983,43:1994–9PubMedGoogle Scholar
  12. 12.
    Cadby PA, Dimitriadis E, Forbes IJ. An analysis of hematoporphyrin derivative. In: Kessel D, Dougherty TJ (eds)Porphyrin Photosensitization. New York-London: Plenum 1983:251–63Google Scholar
  13. 13.
    Andreoni A, Cubeddu R. Fluorescence properties of HPD and its components. In: Andreoni A, Cubeddu R (eds)Porphyrins and Tumor Phototherapy. New York: Plenum 1984:11–21Google Scholar
  14. 14.
    Bonnett R, Berenbaum MC, Kaur H. Chemical and biological studies on hematoporphyrin derivative: an unexpected photosensitization of the brain. In: Andreoni A, Cubeddu R (eds)Porphyrins and Tumor Phototherapy. New York: Plenum 1984:67–80Google Scholar
  15. 15.
    Sun CH, Duzman E, Mellott J et al. Spectroscopic, morphologic and cytotoxic studies on major fractions of hematoporphyrin derivative and Photofrin II.Lasers Surg Med 1987,7:171–9PubMedGoogle Scholar
  16. 16.
    Rimington C, Sommer S, Moan J. Hematoporphyrin ethers—I. Generalized synthesis and chemical properties.Int J Biochem 1987,19:315–20PubMedGoogle Scholar
  17. 17.
    Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. In: Andreoni A, Cubeddu R (eds)Porphyrins and Tumor Phototherapy. New York: Plenum 1984:23–35Google Scholar
  18. 18.
    Kessel D. In vivo fluorescence of tumors after treatment with derivatives of hematoporphyrin.Photochem Photobiol 1986,44:107–8PubMedGoogle Scholar
  19. 19.
    Moan J. Porphyrin photosensitization and phototherapy.Photochem Photobiol 1986,43:681–90PubMedGoogle Scholar
  20. 20.
    Lai JJ, McCaul BW, Smith KM, Straight RC. Polyhematoporphyrin esters: Preparation, properties and biological activity of a new stable derivative of hematoporphyrin for photodynamic therapy. In:Clayton Foundation Conference on Photodynamic Therapy. Los Angeles, CA 1987Google Scholar
  21. 21.
    Fioretti P, Faccini V, Gadducci A, Cozzani I. Monitoring of hematoporphyrin injected in humans and clinical prospects of its use in gynecologic oncology. In: Andreoni A, Cubeddu R (eds)Porphyrins and Tumor Phototherapy. New York: Plenum 1984, 355–61Google Scholar
  22. 22.
    Kessel D. Components of hematoporphyrin derivatives and their tumor-localizing capacity.Cancer Res 1982,42:1703–6PubMedGoogle Scholar
  23. 23.
    Ben Hur E, Rosental I. Photosensitized inactivation of Chinese hamster cells by Phthalocyanines.Photochem Photobiol 1985,42:129–33PubMedGoogle Scholar
  24. 24.
    Chan W-S, Marshall JF, Svensen R et al. Photosensing activity of phthalocyanine dyes screened against tissue culture cells.Photochem Photobiol 1987,45:757–61PubMedGoogle Scholar
  25. 25.
    Tralau CJ, MacRobert PD, Coleridge-Smith H et al. Photodynamic therapy with phthalocyanine sensitization: quantitative studies in a transplantable rat fibrocarcinoma.Br J Cancer 1987,55:389–95PubMedGoogle Scholar
  26. 26.
    Spikes JD. Phthalocyanines as photosensitizers in biological systems and for photodynamic therapy of tumors.Photochem Photobiol 1986,43:691–9PubMedGoogle Scholar
  27. 27.
    Andersson-Engels S, Ankerst J, Montan S et al. Aspects of tumour demarcation in rats by means of laser-induced fluorescence and hematoporphyrin derivatives.Lasers Med Sci 1988,3:239–48Google Scholar
  28. 28.
    Montan S, Svanberg K, Svanberg S. Multicolor imaging and contrast enhancement in cancer-tumor localization using laser-induced fluorescence in Hematoporphyrin-Derivative-bearing tissue.Optics Lett 1985,10:56–8Google Scholar
  29. 29.
    Svanberg K, Kjellén E, Ankerst J et al. Fluorescence studies of Hematoporphyrin Derivative in normal and malignant rat tissue.Cancer Res 1986,46:3803–8PubMedGoogle Scholar
  30. 30.
    Ankerst J, Montán S, Svanberg K, Svanberg S. Laser-induced fluorescence studies of hematoporphyrin derivative (HPD) in normal and malignant rat tissue.Appl Spectr 1984,38:890–6Google Scholar
  31. 31.
    Moan J, Sommer S. Uptake of the components of hematoporphyrin derivatives by cells and tumours.Cancer Lett 198321:167–76PubMedGoogle Scholar
  32. 32.
    Evensen JF, Sommer S, Moan J, Christensen T. Tumor-localizing and photosensitizing properties of the main components of hematoporphyrin derivative.Cancer Res 1984,44:482–6PubMedGoogle Scholar
  33. 33.
    Miyoshi N, Hisazumi H, Ueki O, Hakajima K. Cellular Binding of hematoporphyrin derivative in human bladder cancer cell lines: KK-47.Photochem Photobiol 1984,39:359–63PubMedGoogle Scholar

Copyright information

© Baillière Tindall 1989

Authors and Affiliations

  • S. Andersson-Engels
    • 1
  • J. Ankerst
    • 1
    • 2
  • J. Johansson
    • 1
  • K. Svanberg
    • 1
    • 2
    • 3
  • S. Svanberg
    • 1
  1. 1.Department of PhysicsLund Institute of TechnologyLund
  2. 2.Department of MedicineLund University HospitalLundSweden
  3. 3.Department of OncologyLund University HospitalLundSweden

Personalised recommendations